Skip to Main Content

Though a rival’s Alzheimer’s drug reached the market first, the CEO of Eli Lilly spoke confidently Tuesday about its amyloid-clearing product’s potential to take on Biogen’s recently launched Aduhelm.

Speaking at STAT’s Breakthrough Science Summit, CEO David Ricks said Lilly last month asked the Food and Drug Administration to expedite approval of its drug donanemab for “business reasons, competitive reasons, but more importantly, patient reasons.” 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!